海普瑞(002399.SZ):依諾肝素鈉注射液獲得EMA新增生產商批準
格隆匯6月17日丨海普瑞(002399.SZ)公佈,公司近日收到歐洲藥品管理局(以下簡稱“EMA”)簽發的關於依諾肝素鈉注射液新增成品製造商的批準通知。
本次公司坪山園區預灌封製劑生產線獲得EMA的許可,標誌着公司坪山園區生產的依諾肝素鈉注射液已獲得在歐洲經濟區(EEA)實現商業化的資格,本次獲批將爲公司進一步推進製劑國際化戰略提供更加充足的產能保障,切實提高公司市場競爭力;同時,依託強大的預灌針生產能力,以及公司成熟的自營銷售網絡及渠道,公司助力中國藥企藥品出海歐美市場的戰略將得到有力的支持和推動,對公司未來業務拓展有深遠且積極的影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.